← Human Trials & Peer-Reviewed Studies
Pain perception in knees with circumscribed cartilage lesions is associated with intra-articular IGF-1 expression
Plain-language guide to PMID 21617253 (2011): controlled clinical trial study of IGF-1 LR3 in 42 patients.
Key Facts
- PMID
- 21617253
- Journal
- The American journal of sports medicine
- Year
- 2011
- Study type
- Controlled Clinical Trial
- Authors
- Schmal H et al. (6 authors)
- DOI
- 10.1177/0363546511406851
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in this controlled clinical trial publication.
This study aimed to reveal relations between synovial cytokine levels in knees with circumscribed cartilage defects and pain sensation.
Why It Was Studied
Circumscribed cartilage defects are considered as prearthritic lesions and lead to differential intra-articular cytokine expression.
Mechanisms of associated pain development and influence of smoking behavior are not yet fully understood in humans.
Who Took Part
The abstract describes 42 patients taking part.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
In a clinical trial, knee lavage fluids of 42 patients with circumscribed cartilage lesions treated by either microfracturing (n = 19) or by autologous chondrocyte implantation (n = 23) and fluids of 5 healthy control individuals were prospectively collected.
Preoperative knee pain was evaluated according to frequency and strength; subjective knee function was assessed using a visual analog scale and the International Knee Documentation Committee (IKDC) score.
How the Study Was Run
Synovial concentrations of aggrecan, insulin-like growth factor (IGF)-I, basic fibroblast growth factor (bFGF), interleukin (IL)-1β, bone morphogenetic protein (BMP)-2, and BMP-7 were determined by enzyme-linked immunosorbent assay.
What Was Measured
Topics PubMed links to this paper include Body Mass Index, Cartilage, Cytokines, Insulin-Like Growth Factor I, Knee, Knee Injuries and Orthopedic Procedures.
What This Means in Plain Language
This is a controlled clinical trial of IGF-1 LR3 in 42 patients.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (The American journal of sports medicine), a journal based in United States.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.